GC203 ndi njira yatsopano yochiritsira TIL yosakhala ndi mavairasi yosinthidwa majini yomwe idapangidwa pogwiritsa ntchito nsanja yokulitsa maselo a Juncell Therapeutics ya DeepTIL® komanso nsanja yosinthira majini ya NovaGMP®. DeepTIL® imalola ma TIL kukhala amphamvu mokwanira kotero kuti palibe kuphatikiza kwa IL-2 komwe kudzafunike pambuyo polowetsedwa, ndipo mphamvu ya chithandizo chisanayambike ikhoza kukhala yotsika. NovaGMP® imasintha maselo a T ndi mphamvu yayikulu yofanana ndi vector ya Lentiviral mwanjira yachuma. GC203 idapangidwa ndi interleukin-7 yolumikizidwa ndi nembanemba, yomwe imatha kusunga kulimba kwa maselo a T okumbukira, kuyambitsa maselo amkati oteteza thupi ndikupewa poizoni wa thupi.
Ofufuza adayesa GC203 kwa odwala omwe adapezeka ndi khansa ya m'chiberekero yobwerezabwereza, popanda kuphatikiza kwa IL-2 kapena aggressive lymphodepletion. Cholinga cha kafukufukuyu chinali kudziwa chitetezo ndi mphamvu ya chithandizochi. Odwala onse 20 adalembedwa pakati pa 09/2021 ndi 01/2024 mu kafukufuku wa open-label single-center, pomwe odwala 18 adayesedwa. Odwala omwe adayesedwa anali ndi ECOG PS ya 1 (55.6%) kapena 2 (44.4%) ndipo adalandira apakatikati mwa mankhwala 5 am'mbuyomu (amitundu: 2-11). Odwala 9 (50%) anali ndi zilonda zitatu kapena kuposerapo za chotupa. Kukula kwapakati kwa zilonda zomwe zinali pachiwopsezo kunali 57 (amitundu: 13-146) mm.
GC203 inawonetsa zotsatira zabwino kwa odwala omwe ali ndi khansa ya m'chiberekero yomwe imabwereranso kapena yofalikira. Chitetezo cha khansa chinakula kwambiri poyerekeza ndi mankhwala a TIL, chifukwa cha chithandizo chochepa komanso kuchotsa kuphatikiza kwa IL-2. Zochitika Zoipa Zambiri (AEs) zinali giredi 1 kapena giredi 2 ndipo zitha kuchepetsedwa kapena kuchiritsidwa ndi chithandizo cha zizindikiro. Palibe chochitika cha giredi 5 chomwe chinachitika. Pofika tsiku lomaliza la 01/2024, Objective Response Rate (ORR) yomwe idayesedwa ndi ofufuza inali 33.3% (95% CI: 16.3 - 56.3), kuphatikiza 11.1% Complete Response (CR). Disease Control Rate (DCR) inali 83.3% (95% CI, 60.8 - 94.2). Ndipo chiŵerengero cha Overall Survival (OS) cha miyezi 12 chinali 68.8% (95% CI: 49.3 - 95.9). Avereji ya OS sinali yokhwima pamene deta idadulidwa.
Mu 2023, Ms. H adalowa m'chipatala mu 2023 chifukwa cha vuto la m'chiuno.ndi kupweteka m'chiunoAtafufuzidwa, ma lymph nodes angapo adapezeka kuti akukulirakulira mu retroperitoneum, groin, ndi madera ena, zomwe zidatsimikizira kuti adapezeka ndi khansa yapamwamba ya ovarian. Chifukwa chake Mayi H adapatsidwa chemotherapy, opaleshoni, chithandizo cha immunotherapy, ndi zina zotero, koma zotsatira zake sizinali zabwino, ndipo chotupacho chinabwereranso.
Chifukwa chake, Mayi H adatenga nawo gawo mu mayeso azachipatala a chithandizo cha maselo a TIL GC203, ndipo patatha mwezi umodzi wa chithandizo ndi GC203, chotupacho chinachepa ndi 37.3%.
Mapeto: Kulowetsedwa kwa GC203ili ndi chitetezo chovomerezeka komanso yothandiza kwambiri kwa odwala omwe amachira OC omwe ali ndi mwayi wochepa wopeza chithandizo.
Pakadali pano, pali mayesero ambiri azachipatala a ukadaulo watsopano wothana ndi khansa ku China omwe akufuna odwala. Mukafunsira mankhwala ndi ukadaulo watsopano, mutha kulumikizana ndi Dipatimenti Yapadziko Lonse ya Chipatala cha Oncology ku Beijing South Region.
Nambala ya Foni: 4008803716
Email：myimmnet@163.com
Zolemba
1.https://www.juncell.com/academic-achievements
2.https://www.juncell.com/company-news-76
3.https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.5552
4.http://myimm.net/mianyizhiliao/2037.html
Nthawi yotumizira: Disembala-11-2024